Cagrilintide/semaglutide
Combination drug
From Wikipedia, the free encyclopedia
Cagrilintide/semaglutide, known as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist[1]. It has been proposed as a follow-on to Ozempic, Mounjaro, and Wegovy in obesity and Type II diabetes treatment.[2]
| Combination of | |
|---|---|
| Cagrilintide | Amylin receptor agonist |
| Semaglutide | GLP-1 receptor agonist |
| Clinical data | |
| Trade names | CagriSema |
Applications
CagriSema is under investigation to treat type 2 diabetes and obesity. Preliminary trial results found a greater weight loss compared to either semaglutide or cagrilintide alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone.[3][4] In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, comparable in efficacy to tirzepatide.[5][6]
Trials
CagriSema entered Phase III clinical trials in 2023.[7]
REDEFINE 1
In June 2025, results were published in the New England Journal of Medicine on REDEFINE 1, a 68-week, double-blind, Phase III clinical trial enrolling 3,417 participants, testing weekly cagrilintide 2.4 mg and semaglutide 2.4 mg individually and together versus placebo in obese/overweight subjects with comorbidities. People treated with CagriSema lost 20.4% of their body weight over 68 weeks, versus 11.5% with cagrilintide 2.4 mg alone, 14.9% with semaglutide 2.4 mg alone, and 3.0% with placebo.[8][9]
REDEFINE 2
In June 2025, results were published in the New England Journal of Medicine on REDEFINE 2, a 68-week, double-blind, Phase III clinical trial enrolling 1,206 participants. REDEFINE 2 reported that obese or overweight adult patients with type 2 diabetes lost 13.7% of their weight over 68 weeks with Cagrilintide/semaglutide, compared with 3.1% with placebo.[10][9]
